Compared with afatinib, treatment with osimertinib demonstrates better survival outcomes for patients with T790M-positive non-small cell lung cancer that does not initially respond to EGFR-TKI treatment.
Rita AghjayanEditor https://www.pulmonologyadvisor.com
Rita Aghjayan is the editor of Hematology Advisor. She holds a BS in biology with minors in physics and chemistry from Pace University in New York. Prior to joining Haymarket, Rita conducted research both in quantum physics and microbial ecology.